Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
OS Therapies (OSTX) announced that it received a notice of allowance from the United States Patent & Trademark Office that a patent will be ...
OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of Allowance from the ...
The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...
Ingelheim: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to ...
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...
The FDA has granted Priority Review to Boehringer Ingelheim's new drug application for its non-small cell lung cancer therapy ...
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback